Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Tetratherix Limited ( (AU:TTX) ) is now available.
Tetratherix has signed a global exclusive distribution and supply agreement with Henry Schein, the world’s largest provider of health care solutions to office-based dental and medical practitioners, securing a clear commercialisation pathway for its first bone regeneration product, Tegenix, targeting dental surgery in the US and other major markets. The deal confirms Henry Schein as Tetratherix’s distribution partner, gives Tegenix immediate access to an established global sales network, and aligns with Tetratherix’s plan for a controlled, market-seeding product launch, while construction has begun on an expanded advanced manufacturing facility in New South Wales designed for scalable, regulatory-compliant production to meet anticipated global demand and support future expansion into additional clinical indications.
The most recent analyst rating on (AU:TTX) stock is a Buy with a A$5.76 price target. To see the full list of analyst forecasts on Tetratherix Limited stock, see the AU:TTX Stock Forecast page.
More about Tetratherix Limited
Tetratherix Limited (ASX: TTX) is an Australian medical technology company developing novel clinical products based on a patented synthetic biomaterial polymer platform, with an initial focus on universal bone regeneration solutions for dental surgery and broader future clinical indications in global healthcare markets.
Average Trading Volume: 8,628
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$92.4M
Find detailed analytics on TTX stock on TipRanks’ Stock Analysis page.